Eleanor Lisbon

919 total citations · 1 hit paper
21 papers, 711 citations indexed

About

Eleanor Lisbon is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Eleanor Lisbon has authored 21 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Genetics and 6 papers in Hematology. Recurrent topics in Eleanor Lisbon's work include Hemoglobinopathies and Related Disorders (9 papers), Colorectal Cancer Treatments and Studies (3 papers) and Iron Metabolism and Disorders (3 papers). Eleanor Lisbon is often cited by papers focused on Hemoglobinopathies and Related Disorders (9 papers), Colorectal Cancer Treatments and Studies (3 papers) and Iron Metabolism and Disorders (3 papers). Eleanor Lisbon collaborates with scholars based in United States, United Kingdom and Nigeria. Eleanor Lisbon's co-authors include Neil Stahl, Evan A. Stein, Richard Wu, Yunling Du, María J. Gutiérrez, George D. Yancopoulos, Gary D. Swergold, Douglas Logan, Scott Mellis and William Smith and has published in prestigious journals such as New England Journal of Medicine, Blood and Journal of the American College of Cardiology.

In The Last Decade

Eleanor Lisbon

19 papers receiving 695 citations

Hit Papers

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol 2012 2026 2016 2021 2012 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    2012 505 citations Evan A. Stein, Scott Mellis et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eleanor Lisbon United States 10 440 135 132 103 95 21 711
P. Pfister France 8 329 0.7× 86 0.6× 31 0.2× 51 0.5× 102 1.1× 17 546
Tomas Hala United States 7 499 1.1× 38 0.3× 249 1.9× 119 1.2× 176 1.9× 9 672
Jessica Ray United States 13 160 0.4× 269 2.0× 21 0.2× 68 0.7× 40 0.4× 18 599
Rosa Falcone Italy 20 377 0.9× 190 1.4× 18 0.1× 537 5.2× 53 0.6× 63 1.1k
Chandrasekhar Udata United States 14 167 0.4× 243 1.8× 18 0.1× 50 0.5× 136 1.4× 36 895
Celina Ang United States 16 214 0.5× 232 1.7× 12 0.1× 21 0.2× 54 0.6× 51 956
Raimondo Di Liello Italy 13 71 0.2× 265 2.0× 16 0.1× 44 0.4× 87 0.9× 33 738
Rossana Roncato Italy 18 48 0.1× 284 2.1× 26 0.2× 36 0.3× 77 0.8× 52 907
Samar Alhomoud Saudi Arabia 18 156 0.4× 452 3.3× 38 0.3× 20 0.2× 44 0.5× 35 1.1k
Anshu Marathe United States 11 26 0.1× 183 1.4× 41 0.3× 53 0.5× 72 0.8× 22 559

Countries citing papers authored by Eleanor Lisbon

Since Specialization
Citations

This map shows the geographic impact of Eleanor Lisbon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eleanor Lisbon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eleanor Lisbon more than expected).

Fields of papers citing papers by Eleanor Lisbon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eleanor Lisbon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eleanor Lisbon. The network helps show where Eleanor Lisbon may publish in the future.

Co-authorship network of co-authors of Eleanor Lisbon

This figure shows the co-authorship network connecting the top 25 collaborators of Eleanor Lisbon. A scholar is included among the top collaborators of Eleanor Lisbon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eleanor Lisbon. Eleanor Lisbon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lisbon, Eleanor, R. Clark Brown, Andrew Redfern, et al.. (2025). Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients. Clinical Pharmacology & Therapeutics. 119(1). 120–130.
2.
Saraf, Santosh L., Shehu U. Abdullahi, Modupe Idowu, et al.. (2025). Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week phase 2, multicenter, open-label, dose-finding trial and extension study. Blood. 146(Supplement 1). 4728–4728.
3.
4.
Saraf, Santosh L., Shehu U. Abdullahi, Modupe Idowu, et al.. (2023). Preliminary Results from a Multicenter Phase 2/3 Study of Next-Generation HbS Polymerization Inhibitor GBT021601 for the Treatment of Patients with Sickle Cell Disease. Blood. 142(Supplement 1). 274–274. 7 indexed citations
5.
Abdullahi, Shehu U., Modupe Idowu, William B. Ershler, et al.. (2023). Preliminary Pharmacodynamic Results from a Multicenter Phase 2/3 Study of Next-Generation HbS Polymerization Inhibitor GBT021601 for the Treatment of Patients with Sickle Cell Disease. Blood. 142(Supplement 1). 1155–1155. 1 indexed citations
6.
Idowu, Modupe, Thinh Nguyen, Derek Lewis, et al.. (2022). Pharmacodynamic Results from Phase 1 Studies of GBT021601, a Next-Generation HbS Polymerization Inhibitor for Treatment of Sickle Cell Disease. Blood. 140(Supplement 1). 24–25. 2 indexed citations
7.
8.
9.
Andemariam, Biree, Sanne Lugthart, Timothy Mant, et al.. (2020). Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients. Blood. 136(Supplement 1). 29–30. 1 indexed citations
10.
Johansson, Susanne, David P. Rosenbaum, Johan Palm, et al.. (2017). Tenapanor administration and the activity of the H+‐coupled transporter PepT1 in healthy volunteers. British Journal of Clinical Pharmacology. 83(9). 2008–2014. 10 indexed citations
11.
12.
Vishwanathan, Karthick, Paul A. Dickinson, Khanh Bui, et al.. (2017). The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers. The Journal of Clinical Pharmacology. 58(4). 474–484. 45 indexed citations
13.
So, Karen, Paul Martin, Yifan Huang, et al.. (2016). Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials. European Journal of Clinical Pharmacology. 73(2). 175–184. 23 indexed citations
14.
Flanagan, Talia, et al.. (2016). Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies. European Journal of Clinical Pharmacology. 73(2). 185–195. 9 indexed citations
15.
Vishwanathan, Karthick, Paul A. Dickinson, Khanh Bui, et al.. (2015). Abstract B153: Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291. Molecular Cancer Therapeutics. 14(12_Supplement_2). B153–B153. 9 indexed citations
16.
Johansson, Susanne, Jessica Read, Stuart Oliver, et al.. (2014). Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine. Clinical Pharmacokinetics. 53(9). 837–847. 52 indexed citations
17.
Stein, Evan A., Scott Mellis, George D. Yancopoulos, et al.. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. Obstetrical & Gynecological Survey. 67(7). 413–414. 10 indexed citations
18.
Stein, Evan A., Scott Mellis, George D. Yancopoulos, et al.. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. New England Journal of Medicine. 366(12). 1108–1118. 505 indexed citations breakdown →
19.
Swergold, Gary D., et al.. (2011). REGN727/SAR236553, A FULLY HUMAN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) MONOCLONAL ANTIBODY: EFFECTS ON SAFETY AND LIPID AND LIPOPROTEIN PROFILES WHEN ADMINISTERED SUBCUTANEOUSLY. Journal of the American College of Cardiology. 57(14). E2023–E2023. 3 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. Pfister Breakdown of academic impact, for papers by Tomas Hala Breakdown of academic impact, for papers by Jessica Ray Breakdown of academic impact, for papers by Rosa Falcone Breakdown of academic impact, for papers by Chandrasekhar Udata Breakdown of academic impact, for papers by Celina Ang Breakdown of academic impact, for papers by Raimondo Di Liello Breakdown of academic impact, for papers by Rossana Roncato Breakdown of academic impact, for papers by Samar Alhomoud Breakdown of academic impact, for papers by Anshu Marathe
Rankless by CCL
2026